%0 Journal Article
%T Cost-utility analysis of 5-fluorouracil and capecitabine for adjuvant treatment in locally advanced rectal cancer
%A Apiradee Kridakara
%A Chokaew Tovanabutra
%A Imjai Chitapanarux
%A Kanokpis Townamchai
%A Kanyarat Katanyoo
%A Kittisak Chomprasert
%A Marisa Chongthanakorn
%A Pooriwat Muangwong
%A Rungarun Jiratrachu
%A Somvilai Chakrabandhu
%A Tharatorn Tungkasamit
%J SCIE-indexed Journal
%D 2018
%X Colorectal cancer (CRC) is the third common cause of malignancy in the world. The incidence and death rate from this cancer has a trend increasingly, especially in developing countries (1). Chemotherapy and radiation therapy (RT) are considered as appropriated pre-operative and post-operative treatments for locally advanced rectal cancer (LARC), stage II (T3¨C4N0M0) and III (T1¨C4N1¨C2M0). Intravenous administration of 5-fluorouracil (5-FU)-based regimen or oral administration of fluoropyrimidine as capecitabine is commonly used in concurrent time with RT and adjuvant treatment. In 2012, a landmark study from Germany reported that capecitabine could be substituted for 5-FU in pre-operative or post-operative setting for rectal cancer because of its non-inferiority of efficacy and less hemato-toxicity than 5-FU (2). Therefore, capecitabine is proved to be used as an adjuvant setting in NCCN guideline for rectal cancer (3)
%U http://jgo.amegroups.com/article/view/18657/html